Stents Peripheral

Peripheral stents are used to open narrow and hardening arteries that supply blood to the legs and feet.

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

Feature | Stents | February 11, 2020 | Saloni Walimbe
Cardiovascular diseases (CVDs) are among the leading causes of death across the globe. For patients suffering from high...
The repuncturable Supera vascular mimetic peripheral stent system from Abbott Vascular was shown to manage bulky, heavily calcified CFA disease due to its extreme crush resistance in the VMI-CFA study. #VIVA #VIVA19 #VIVA2019

The repuncturable Supera vascular mimetic peripheral stent system from Abbott Vascular was shown to manage bulky, heavily calcified CFA disease due to its extreme crush resistance in the VMI-CFA study.

News | Stents Carotid | November 11, 2019
November 11, 2019 — Although common femoral artery (CFA) endarterectomy is still considered the gold standard treatment...
News | Stents Bioresorbable | November 07, 2019
November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was taken off the market due...
The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients. #VIVA19 #VIVA #VIVA2019

The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients.

 

Feature | Stents Peripheral | November 06, 2019 | Dave Fornell, Editor
November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES)...
Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA
News | Peripheral Artery Disease (PAD) | November 06, 2019
November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-eluting...
Viva conference late breaking clinical trials, #VIVA19 #VIVA #VIVA2019
Feature | VIVA | November 14, 2019
November 14, 2019 — The results of the 21 late-breaking clinical trials presented for the first time at Vascular...
FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor
August 28, 2019 — The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the...
Endovascular-first Approach Equal to Open Surgery in Avoiding Amputation for Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | August 01, 2019
August 1, 2019 — Less-invasive procedures to open severely clogged leg arteries were as good at helping people survive...
Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019
April 15, 2019 – Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack...
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003,...
FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers...
Videos | October 11, 2018
Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston Scientific,...
Veryan Medical's BioMimics 3D Stent Receives PMA Approval
Technology | Stents Peripheral | October 05, 2018
October 5, 2018 — Veryan Medical Ltd has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System...
SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection
News | Peripheral Artery Disease (PAD) | May 15, 2018
May 15, 2018 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to...